Revision History

A Phase 3 clinical trial showed that daraxonrasib, an oral RAS inhibitor made by Revolution Medicines, doubled median overall survival from 6.7 to 13.2 months in patients with previously treated metastatic pancreatic cancer — the first drug to successfully target the KRAS mutation driving over 90% of cases. While the results are unprecedented for this cancer type, questions remain about pricing, global access, and whether the benefit extends to first-line treatment.